Novel Coronavirus Inactivated Vaccine Market Report – Research, Industry Analysis Reports and Market Demands

Global Novel Coronavirus Inactivated Vaccine Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Novel Coronavirus Inactivated Vaccine Consumption Value by Type: 2020 Versus 2024 Versus 2031
- 1.3.2 Adult
- 1.3.3 Child
1.4 Market Analysis by Application
- 1.4.1 Overview: Global Novel Coronavirus Inactivated Vaccine Consumption Value by Application: 2020 Versus 2024 Versus 2031
- 1.4.2 Hospital
- 1.4.3 Clinic
1.5 Global Novel Coronavirus Inactivated Vaccine Market Size & Forecast
- 1.5.1 Global Novel Coronavirus Inactivated Vaccine Consumption Value (2020 & 2024 & 2031)
- 1.5.2 Global Novel Coronavirus Inactivated Vaccine Sales Quantity (2020-2031)
- 1.5.3 Global Novel Coronavirus Inactivated Vaccine Average Price (2020-2031)

2 Manufacturers Profiles

3 Competitive Environment: Novel Coronavirus Inactivated Vaccine by Manufacturer

3.1 Global Novel Coronavirus Inactivated Vaccine Sales Quantity by Manufacturer (2020-2025)
3.2 Global Novel Coronavirus Inactivated Vaccine Revenue by Manufacturer (2020-2025)
3.3 Global Novel Coronavirus Inactivated Vaccine Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
- 3.4.1 Producer Shipments of Novel Coronavirus Inactivated Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2024
- 3.4.2 Top 3 Novel Coronavirus Inactivated Vaccine Manufacturer Market Share in 2024
- 3.4.3 Top 6 Novel Coronavirus Inactivated Vaccine Manufacturer Market Share in 2024
3.5 Novel Coronavirus Inactivated Vaccine Market: Overall Company Footprint Analysis
- 3.5.1 Novel Coronavirus Inactivated Vaccine Market: Region Footprint
- 3.5.2 Novel Coronavirus Inactivated Vaccine Market: Company Product Type Footprint
- 3.5.3 Novel Coronavirus Inactivated Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Novel Coronavirus Inactivated Vaccine Market Size by Region
- 4.1.1 Global Novel Coronavirus Inactivated Vaccine Sales Quantity by Region (2020-2031)
- 4.1.2 Global Novel Coronavirus Inactivated Vaccine Consumption Value by Region (2020-2031)
- 4.1.3 Global Novel Coronavirus Inactivated Vaccine Average Price by Region (2020-2031)
4.2 North America Novel Coronavirus Inactivated Vaccine Consumption Value (2020-2031)
4.3 Europe Novel Coronavirus Inactivated Vaccine Consumption Value (2020-2031)
4.4 Asia-Pacific Novel Coronavirus Inactivated Vaccine Consumption Value (2020-2031)
4.5 South America Novel Coronavirus Inactivated Vaccine Consumption Value (2020-2031)
4.6 Middle East & Africa Novel Coronavirus Inactivated Vaccine Consumption Value (2020-2031)

5 Market Segment by Type

5.1 Global Novel Coronavirus Inactivated Vaccine Sales Quantity by Type (2020-2031)
5.2 Global Novel Coronavirus Inactivated Vaccine Consumption Value by Type (2020-2031)
5.3 Global Novel Coronavirus Inactivated Vaccine Average Price by Type (2020-2031)

6 Market Segment by Application

6.1 Global Novel Coronavirus Inactivated Vaccine Sales Quantity by Application (2020-2031)
6.2 Global Novel Coronavirus Inactivated Vaccine Consumption Value by Application (2020-2031)
6.3 Global Novel Coronavirus Inactivated Vaccine Average Price by Application (2020-2031)

7 North America

7.1 North America Novel Coronavirus Inactivated Vaccine Sales Quantity by Type (2020-2031)
7.2 North America Novel Coronavirus Inactivated Vaccine Sales Quantity by Application (2020-2031)
7.3 North America Novel Coronavirus Inactivated Vaccine Market Size by Country
- 7.3.1 North America Novel Coronavirus Inactivated Vaccine Sales Quantity by Country (2020-2031)
- 7.3.2 North America Novel Coronavirus Inactivated Vaccine Consumption Value by Country (2020-2031)
- 7.3.3 United States Market Size and Forecast (2020-2031)
- 7.3.4 Canada Market Size and Forecast (2020-2031)
- 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

8.1 Europe Novel Coronavirus Inactivated Vaccine Sales Quantity by Type (2020-2031)
8.2 Europe Novel Coronavirus Inactivated Vaccine Sales Quantity by Application (2020-2031)
8.3 Europe Novel Coronavirus Inactivated Vaccine Market Size by Country
- 8.3.1 Europe Novel Coronavirus Inactivated Vaccine Sales Quantity by Country (2020-2031)
- 8.3.2 Europe Novel Coronavirus Inactivated Vaccine Consumption Value by Country (2020-2031)
- 8.3.3 Germany Market Size and Forecast (2020-2031)
- 8.3.4 France Market Size and Forecast (2020-2031)
- 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
- 8.3.6 Russia Market Size and Forecast (2020-2031)
- 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

9.1 Asia-Pacific Novel Coronavirus Inactivated Vaccine Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Novel Coronavirus Inactivated Vaccine Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Novel Coronavirus Inactivated Vaccine Market Size by Region
- 9.3.1 Asia-Pacific Novel Coronavirus Inactivated Vaccine Sales Quantity by Region (2020-2031)
- 9.3.2 Asia-Pacific Novel Coronavirus Inactivated Vaccine Consumption Value by Region (2020-2031)
- 9.3.3 China Market Size and Forecast (2020-2031)
- 9.3.4 Japan Market Size and Forecast (2020-2031)
- 9.3.5 South Korea Market Size and Forecast (2020-2031)
- 9.3.6 India Market Size and Forecast (2020-2031)
- 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
- 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

10.1 South America Novel Coronavirus Inactivated Vaccine Sales Quantity by Type (2020-2031)
10.2 South America Novel Coronavirus Inactivated Vaccine Sales Quantity by Application (2020-2031)
10.3 South America Novel Coronavirus Inactivated Vaccine Market Size by Country
- 10.3.1 South America Novel Coronavirus Inactivated Vaccine Sales Quantity by Country (2020-2031)
- 10.3.2 South America Novel Coronavirus Inactivated Vaccine Consumption Value by Country (2020-2031)
- 10.3.3 Brazil Market Size and Forecast (2020-2031)
- 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

11.1 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Novel Coronavirus Inactivated Vaccine Market Size by Country
- 11.3.1 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Quantity by Country (2020-2031)
- 11.3.2 Middle East & Africa Novel Coronavirus Inactivated Vaccine Consumption Value by Country (2020-2031)
- 11.3.3 Turkey Market Size and Forecast (2020-2031)
- 11.3.4 Egypt Market Size and Forecast (2020-2031)
- 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
- 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

12.1 Novel Coronavirus Inactivated Vaccine Market Drivers
12.2 Novel Coronavirus Inactivated Vaccine Market Restraints
12.3 Novel Coronavirus Inactivated Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Novel Coronavirus Inactivated Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Novel Coronavirus Inactivated Vaccine
13.3 Novel Coronavirus Inactivated Vaccine Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Novel Coronavirus Inactivated Vaccine Typical Distributors
14.3 Novel Coronavirus Inactivated Vaccine Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Novel Coronavirus Inactivated Vaccine market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Novel Coronavirus Inactivated Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Novel Coronavirus Inactivated Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Novel Coronavirus Inactivated Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Novel Coronavirus Inactivated Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Novel Coronavirus Inactivated Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Novel Coronavirus Inactivated Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Novel Coronavirus Inactivated Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Inovio Pharmaceuticals, Moderna, GlaxoSmithKine, Pfizer, Johnson&Johnson, Heat Biologics, Sanofi, Beijing Institute of Biological Products Co., Ltd, Beijing Kexing Zhongwei Biotechnology Co., Ltd, Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Novel Coronavirus Inactivated Vaccine market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Adult
Child
Market segment by Application
Hospital
Clinic
Major players covered
Inovio Pharmaceuticals
Moderna
GlaxoSmithKine
Pfizer
Johnson&Johnson
Heat Biologics
Sanofi
Beijing Institute of Biological Products Co., Ltd
Beijing Kexing Zhongwei Biotechnology Co., Ltd
Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd
Wuhan Institute of Biological Products Co., Ltd
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Novel Coronavirus Inactivated Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Novel Coronavirus Inactivated Vaccine, with price, sales quantity, revenue, and global market share of Novel Coronavirus Inactivated Vaccine from 2020 to 2025.
Chapter 3, the Novel Coronavirus Inactivated Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Novel Coronavirus Inactivated Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Novel Coronavirus Inactivated Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Novel Coronavirus Inactivated Vaccine.
Chapter 14 and 15, to describe Novel Coronavirus Inactivated Vaccine sales channel, distributors, customers, research findings and conclusion.

Buy now